Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)*

Organization & Developments: Praxis Precision Medicines

Parents

*Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by central nervous system (“CNS”) disorders characterized by neuronal imbalance
2022: Praxis Precision Medicines (PRAX) Investor Presentation - Slideshow_ seekingalpha.com
2024: Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
2024: Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals
2024: Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
2024: Praxis Precision Medicines: Multiple Potential Drivers
2024: Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
2025: Praxis flouts phase 3 futility finding, forging ahead with tremor trial despite interim setback
2025: Praxis Suffers Clinical Trial Setback: What's Next for Their $469M Pipeline?
2025: Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
2025: Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide
2026: #7 Ulixacaltamide, Company: Praxis Precision Medicines Used for: Essential tremor Est. 2032 sales: $2.1 billion